Alzheimer's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Alzheimer's Disease, including details on diagnosis, memory loss, heredity, treatment, medication.

Volume 1 (2004), Issue 5 (December)

1. Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease.
   Brain Res Brain Res Rev, 47(1): 275-89. [Abstract] [Full-text]
2. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease.
   Neurobiol Dis, 17(3): 500-6. [Abstract] [Full-text]
3. Hemoglobin promotes Abeta oligomer formation and localizes in neurons and amyloid deposits.
   Neurobiol Dis, 17(3): 367-77. [Abstract] [Full-text]
4. Genetic testing has no place as a routine diagnostic test in sporadic and familial cases of Alzheimer's disease.
   J Am Geriatr Soc, 52(12): 2110-3. [Abstract] [Full-text]
5. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?
   J Am Geriatr Soc, 52(12): 2082-7. [Abstract] [Full-text]
6. Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides.
   J Biol Inorg Chem, 9(8): 954-60. [Abstract] [Full-text]
7. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.
   J Clin Invest, 114(11): 1624-34. [Abstract] [Full-text]
8. Obesity-related leptin regulates Alzheimer's Abeta.
   FASEB J, 18(15): 1870-8. [Abstract] [Full-text]
9. Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease.
   J Biol Chem, 279(50): 51958-64. [Abstract] [Full-text]
10. Neuronal membrane cholesterol loss enhances amyloid peptide generation.
    J Cell Biol, 167(5): 953-60. [Abstract] [Full-text]
11. A lipid boundary separates APP and secretases and limits amyloid beta-peptide generation.
    J Cell Biol, 167(5): 809-12. [Abstract] [Full-text]
12. Diminished aromatase immunoreactivity in the hypothalamus, but not in the basal forebrain nuclei in Alzheimer's disease.
    Neurobiol Aging, 26(2): 173-94. [Abstract] [Full-text]
13. Decreased EEG synchronization in Alzheimer's disease and mild cognitive impairment.
    Neurobiol Aging, 26(2): 165-71. [Abstract] [Full-text]
14. Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging.
    Neurobiol Aging, 26(2): 157-63. [Abstract] [Full-text]
15. A new strategy to combat Alzheimer's disease. Combining radical-scavenging potential with metal-protein-attenuating ability in one molecule.
    Bioorg Med Chem Lett, 15(1): 21-4. [Abstract] [Full-text]
16. Protein quality control in Alzheimer's disease by the ubiquitin proteasome system.
    Prog Neurobiol, 74(5): 249-70. [Abstract] [Full-text]
17. Early dysregulation of hippocampal proteins in transgenic rats with Alzheimer's disease-linked mutations in amyloid precursor protein and presenilin 1.
    Brain Res Mol Brain Res, 132(2): 241-59. [Abstract] [Full-text]
18. Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease.
    Behav Brain Res, 156(2): 225-32. [Abstract] [Full-text]
19. Alzheimer's disease as a disorder of dynamic brain self-organization.
    Prog Brain Res, 147: 355-78. [Abstract] [Full-text]
20. In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent.
    Magn Reson Med, 52(6): 1263-71. [Abstract] [Full-text]
21. Benchmarking a test of temporal orientation with data from american and taiwanese persons with Alzheimer's disease and american normal elderly.
    Neuroepidemiology, 24(1): 110-6. [Abstract] [Full-text]
22. Genetic association of low density lipoprotein receptor and Alzheimer's disease.
    Neurobiol Aging, 26(1): 1-7. [Abstract] [Full-text]
23. Positive aspects of caregiving and adaptation to bereavement.
    Psychol Aging, 19(4): 668-75. [Abstract] [Full-text]
24. A 4-year follow-up of very old patients presenting with frontal-subcortical dysfunction compared with Alzheimer's disease patients.
    Gerontology, 51(1): 62-5. [Abstract] [Full-text]
25. Exaggerated plasma fibrin formation (D-dimer) in elderly Alzheimer caregivers as compared to noncaregiving controls.
    Gerontology, 51(1): 7-13. [Abstract] [Full-text]
26. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention.
    J Neurosci, 24(49): 11120-6. [Abstract] [Full-text]
27. Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging.
    Neuroscience, 130(3): 667-84. [Abstract] [Full-text]
28. Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis.
    Neuroscience, 130(3): 657-66. [Abstract] [Full-text]
29. Astrocytic calcium/zinc binding protein S100A6 over expression in Alzheimer's disease and in PS1/APP transgenic mice models.
    Biochim Biophys Acta, 1742(1): 161-8. [Abstract] [Full-text]
30. Detection of age-dependent brain injury in a mouse model of brain amyloidosis associated with Alzheimer's disease using magnetic resonance diffusion tensor imaging.
    Exp Neurol, 191(1): 77-85. [Abstract] [Full-text]
31. Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study.
    Neuroimage, 23(4): 1450-9. [Abstract] [Full-text]
32. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
    Prog Neuropsychopharmacol Biol Psychiatry, 28(8): 1313-22. [Abstract] [Full-text]
33. Psychometric performance of an assessment scale for strain in nursing care: the M-NCAS.
    Health Qual Life Outcomes, 2: 62. [Abstract] [Full-text]
34. Neuropsychological performance in early and late onset Alzheimer's disease: comparisons in a memory clinic population.
    Int J Geriatr Psychiatry, 19(12): 1140-7. [Abstract] [Full-text]
35. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
    Dement Geriatr Cogn Disord, 19(1): 51-6. [Abstract] [Full-text]
36. Depressive symptoms increase the likelihood of cognitive impairment in elderly people with subclinical Alzheimer pathology.
    Dement Geriatr Cogn Disord, 19(1): 46-50. [Abstract] [Full-text]
37. Association analysis for the muscarinic M1 receptor genetic polymorphisms and Alzheimer's disease.
    Dement Geriatr Cogn Disord, 19(1): 42-5. [Abstract] [Full-text]
38. Perception of emotion on faces in frontotemporal dementia and Alzheimer's disease: a longitudinal study.
    Dement Geriatr Cogn Disord, 19(1): 37-41. [Abstract] [Full-text]
39. Motivational symptoms of depression mask preclinical Alzheimer's disease in elderly subjects.
    Dement Geriatr Cogn Disord, 19(1): 31-6. [Abstract] [Full-text]
40. [18F]FDG-PET in patients with Alzheimer's disease: marker of disease spread.
    Dement Geriatr Cogn Disord, 19(1): 24-30. [Abstract] [Full-text]
41. Rivastigmine as a modulator of the neuronal glutamate transporter rEAAC1 mRNA expression.
    Dement Geriatr Cogn Disord, 19(1): 18-23. [Abstract] [Full-text]
42. The French Addenbrooke's cognitive examination is effective in detecting dementia in a French-speaking population.
    Dement Geriatr Cogn Disord, 19(1): 15-7. [Abstract] [Full-text]
43. Current smoking and response to cholinesterase inhibitor therapy in Alzheimer's disease.
    Dement Geriatr Cogn Disord, 19(1): 11-4. [Abstract] [Full-text]
44. Decreased release of the angiogenic peptide vascular endothelial growth factor in Alzheimer's disease: recovering effect with insulin and DHEA sulfate.
    Dement Geriatr Cogn Disord, 19(1): 1-10. [Abstract] [Full-text]
45. APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study.
    Arch Neurol, 61(12): 1930-4. [Abstract] [Full-text]
46. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease.
    Arch Neurol, 61(12): 1859-64. [Abstract] [Full-text]
47. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial.
    Arch Neurol, 61(12): 1852-6. [Abstract] [Full-text]
48. Studies on homocysteine plasma levels in Alzheimer's patients. Relevance for neurodegeneration.
    J Neural Transm, 112(1): 163-9. [Abstract] [Full-text]
49. The acetylcholine innervation of cerebral cortex: new data on its normal development and its fate in the hAPP(SW,IND) mouse model of Alzheimer's disease.
    J Neural Transm, 112(1): 149-62. [Abstract] [Full-text]
50. Mixed dementia: emerging concepts and therapeutic implications.
    JAMA, 292(23): 2901-8. [Abstract] [Full-text]
51. Hemispheric asymmetries of hypometabolism associated with semantic memory impairment in Alzheimer's disease: a study using positron emission tomography with fluorodeoxyglucose-F18.
    Psychiatry Res, 132(2): 159-72. [Abstract] [Full-text]
52. Impaired sustained attention and error-induced stereotypy in the aged Ts65Dn mouse: a mouse model of Down syndrome and Alzheimer's disease.
    Behav Neurosci, 118(6): 1196-205. [Abstract] [Full-text]
53. The overexpression of presenilin2 and Alzheimer's-disease-linked presenilin2 variants influences TRPC6-enhanced Ca2+ entry into HEK293 cells.
    Cell Signal, 17(4): 437-45. [Abstract] [Full-text]
54. Effects of donepezil on Alzheimer's disease: the relationship between cognitive function and rapid eye movement sleep.
    Psychiatry Clin Neurosci, 58(6): 660-5. [Abstract] [Full-text]
55. Structural correlates of early and late onset Alzheimer's disease: voxel based morphometric study.
    J Neurol Neurosurg Psychiatry, 76(1): 112-4. [Abstract] [Full-text]
56. EEG coherence reflects regional corpus callosum area in Alzheimer's disease.
    J Neurol Neurosurg Psychiatry, 76(1): 109-11. [Abstract] [Full-text]
57. Disturbance of sensory filtering in dementia with Lewy bodies: comparison with Parkinson's disease dementia and Alzheimer's disease.
    J Neurol Neurosurg Psychiatry, 76(1): 106-8. [Abstract] [Full-text]
58. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age.
    J Neurol Neurosurg Psychiatry, 76(1): 103-5. [Abstract] [Full-text]
59. Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve.
    J Neurol Neurosurg Psychiatry, 76(1): 15-23. [Abstract] [Full-text]
60. Mice transgenic for Alzheimer disease beta-amyloid develop lens cataracts that are rescued by antioxidant treatment.
    Free Radic Biol Med, 38(2): 258-61. [Abstract] [Full-text]
61. Can a herpes simplex virus type 1 neuroinvasive score be correlated to other risk factors in Alzheimer's disease?
    Med Hypotheses, 64(2): 320-7. [Abstract] [Full-text]
62. Music, memory, and Alzheimer's disease: is music recognition spared in dementia, and how can it be assessed?
    Med Hypotheses, 64(2): 229-35. [Abstract] [Full-text]
63. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains.
    J Neurochem, 92(1): 171-82. [Abstract] [Full-text]
64. MALDI mass spectrometric imaging of biological tissue sections.
    Mech Ageing Dev, 126(1): 177-85. [Abstract] [Full-text]
65. Elevation of the level and activity of acid ceramidase in Alzheimer's disease brain.
    Eur J Neurosci, 20(12): 3489-97. [Abstract] [Full-text]
66. Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer's disease patients.
    J Med Virol, 75(2): 300-6. [Abstract] [Full-text]
67. Tau and src family tyrosine kinases.
    Biochim Biophys Acta, 1739(2): 323-30. [Abstract] [Full-text]
68. Pinning down phosphorylated tau and tauopathies.
    Biochim Biophys Acta, 1739(2): 311-22. [Abstract] [Full-text]
69. Can tau filaments be both physiologically beneficial and toxic?
    Biochim Biophys Acta, 1739(2): 260-7. [Abstract] [Full-text]
70. Mutations causing neurodegenerative tauopathies.
    Biochim Biophys Acta, 1739(2): 240-50. [Abstract] [Full-text]
71. Tau, tangles, and Alzheimer's disease.
    Biochim Biophys Acta, 1739(2): 216-23. [Abstract] [Full-text]
72. Tau modifiers as therapeutic targets for Alzheimer's disease.
    Biochim Biophys Acta, 1739(2): 211-5. [Abstract] [Full-text]
73. Tau pathology in Alzheimer disease and other tauopathies.
    Biochim Biophys Acta, 1739(2): 198-210. [Abstract] [Full-text]
74. Pathways of tau fibrillization.
    Biochim Biophys Acta, 1739(2): 167-78. [Abstract] [Full-text]
75. Tau aggregation is driven by a transition from random coil to beta sheet structure.
    Biochim Biophys Acta, 1739(2): 158-66. [Abstract] [Full-text]
76. Transcriptional and conformational changes of the tau molecule in Alzheimer's disease.
    Biochim Biophys Acta, 1739(2): 150-7. [Abstract] [Full-text]
77. Add Alzheimer's disease to the list of autoimmune diseases.
    Med Hypotheses, 64(3): 458-63. [Abstract] [Full-text]
78. Impaired Pavlovian cued fear conditioning in Tg2576 mice expressing a human mutant amyloid precursor protein gene.
    Behav Brain Res, 157(1): 107-17. [Abstract] [Full-text]
79. Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen.
    Behav Brain Res, 157(1): 91-8. [Abstract] [Full-text]
80. Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576.
    Neuropharmacology, 48(1): 93-104. [Abstract] [Full-text]
81. Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease.
    J Pineal Res, 38(1): 10-6. [Abstract] [Full-text]
82. Interaction between a rat model of cerebral ischemia and beta-amyloid toxicity: inflammatory responses.
    Stroke, 36(1): 107-12. [Abstract] [Full-text]
83. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Mech Ageing Dev, 126(2): 317-26. [Abstract] [Full-text]
84. Glutathione S-transferase hGSTM3 and ageing-associated neurodegeneration: relationship to Alzheimer's disease.
    Mech Ageing Dev, 126(2): 309-15. [Abstract] [Full-text]
85. The expression of calcium/calmodulin-dependent protein kinase II-alpha in the hippocampus of patients with Alzheimer's disease and its links with AD-related pathology.
    Brain Res, 1031(1): 101-8. [Abstract] [Full-text]
86. Dementia does not explain correlation between age and scores on Boston Naming Test.
    Arch Clin Neuropsychol, 20(1): 129-33. [Abstract] [Full-text]
87. Proteasome inhibition and Tau proteolysis: an unexpected regulation.
    FEBS Lett, 579(1): 1-5. [Abstract] [Full-text]
88. Validation of the Guidelines for the Diagnosis of Dementia and Alzheimer's Disease of the Italian Neurological Society. Study in 72 Italian neurological centres and 1549 patients.
    Neurol Sci, 25(5): 289-95. [Abstract] [Full-text]
89. Mortality in Alzheimer's disease: a comparative prospective Korean study in the community and nursing homes.
    Int J Geriatr Psychiatry, 20(1): 26-34. [Abstract] [Full-text]

© 2004-2008 Alzheimer's Disease Research Today. All Rights Reserved.